Verso — Proxy Contest (January 2020)
41 slides from Verso's proxy contest presentation, Jan 6, 2020
Slide 1: Highly Qualified, Diverse and Newly Refreshed Board Executing on Strategic Transformation
Highly Qualified, Diverse and Newly Refreshed Board Executing on Strategic Transformation to Create Value Investor Briefing Material January 2020
Slide 2: Forward-Looking Statements
Forward - Looking Statements In this presentation, all statements that are not purely historical facts are forward - looking statements within the meaning of S ection 27A of the Securities Act of 1933, as amended, or “Securities Act,” and Section 21E of the Securities Exchange Act of 1934, as amende
Slide 3: Discussion Agenda
I. Executive Summary II. Verso’s Strategy and Performance III. Corporate Governance Improvements IV. Atlas/Blue Wolf’s Intentions and Claims V. Appendix A VI. Appendix B Discussion Agenda 2
Slide 4: Executive Summary
Lapetus Capital II LLC (“Lapetus”, and together with its affiliates, “Atlas”) and BW Coated LLC (“BW Coated” and together with its af fil iates, “Blue Wolf”) will, collectively with Atlas, be referred to herein as “Atlas / Blue Wolf” Verso Board and Management: Track Record of Strong Performance Ver
Slide 5: Verso's Strategy and Performance
Verso’s Strategy and Performance
Slide 6: About Verso
About Verso 5 Coated Graphic Papers Leading producer in North America Miamisburg, Ohio Headquarters $2.55 billion in Sales for the 12 months Ended September 30, 2019 ~2.7 million tons Total annual paper production capacity ~3,750 Employees in North America 6 Mills Operating and has 5 low cost integr
Slide 7: Returning Significant Capital to Stockholders through Pixelle Transaction
Returning Significant Capital to Stockholders through Pixelle Transaction 6 The Board takes a disciplined approach to capital allocation and is committed to strategically deploying capital to the areas wh ere it believes it can drive the greatest returns for stockholders over the long - term. Verso’
Slide 8: Total Stockholder Return Outperforming Peers and Index
Total Stockholder Return Outperforming Peers and Index 7 Verso has outperformed both our peer group and the Russell 2000, with 49% appreciation over the last three years, versus 37% and 33%, respectively Markets recognizing the success of our operating strategy and strategic review (1) The peer grou
Slide 9: Executing the Right Strategy, Pre-Transaction (P&L)
Executing the Right Strategy, Pre - Transaction (P&L) 8 Key Metrics 2017* LTM Q319 Income Statement Net Sales $M 2,461 2,552 Net Income (Loss) $M (30) 40 Adjusted EBITDA 1 $M 134 273 Adj. EBITDA 1 Margin % 5.4% 10.7% 2017* LTM Q319 ∆ ∆% Shipments (000 tons) Paper 2,704 2,499 (205) (8)% Pulp 255 233
Slide 10: Executing the Right Strategy, Pre-Transaction (Balance Sheet & Cash Flow)
Executing the Right Strategy, Pre - Transaction (Balance Sheet & Cash Flow) 9 Liquidity, Net Debt and Cash Flow Strong liquidity with cash from operations funding requirements. Net Debt 1 ($M) 1 st Quarter End Post - Emergence 9 /30/16 12/31/16 12/31/17 12/31/18 Last Public Report 9/30/19 Not Public
Slide 11: Executing the Right Strategy Following Pixelle Transaction
Executing the Right Strategy Following Pixelle Transaction 10 Increasing Flexibility to Capitalize on Market Opportunities, Adapt to Changing Environment and Implement Transformational Change The Board is continuing its strategic review best position the Company to capitalize on market dislocation,
Slide 12: Verso Post Transaction Profile
10 ▪ Remaining mills located in Quinnesec and Escanaba, Michigan; Wisconsin Rapids, Wisconsin and Duluth, Minnesota. ▪ Streamlined assets into attractive markets and continued improvement to cost structure with available capital through proceeds and operating cash flow. ▪ Manageable pension position
Slide 13: Positive Market Reaction to Pixelle Transaction
12 $0.00 $5.00 $10.00 $15.00 $20.00 $25.00 $30.00 $35.00 $40.00 8/1/2016 2/1/2017 8/1/2017 2/1/2018 8/1/2018 2/1/2019 8/1/2019 Pixelle Transaction Announced (November 2019) Verso Emergence from Bankruptcy (July 2016) Positive Market Reaction to Pixelle Transaction
Slide 14: Corporate Governance Improvements
Corporate Governance Improvements
Slide 15: Corporate Governance Improvements — Board Composition
Corporate Governance Improvements — Board Composition 14 Five of seven new director nominees in 2019 If elected, six of seven directors will be independent with our CEO as the remaining member Pursuing majority voting standard through proposal at 2020 Annual Meeting, seeking to replace existing stan
Slide 16: Verso's Nominees are Highly Qualified and Diverse
Verso’s Nominees are Highly Qualified and Diverse 15 Jay Shuster Managing Member of Shuster Group, advising on strategic and operational planning, M&A, turnaround management issues Adam St. John — CEO 27 - year paper veteran, with senior manufacturing and operational roles at Verso and Georgia Pacif
Slide 17: Highly Experienced Board with Right Expertise to Drive Stockholder Value
Highly Experienced Board with Right Expertise to Drive Stockholder Value 16 Public Company Board Experience CEO / CFO / COO Finance and M&A Operations Transformation / Strategy Paper Industry Independent Diverse Governance Dr. Robert K. Beckler ✓ ✓ ✓ ✓ ✓ ✓ Paula Cholmondeley ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Randy
Slide 18: Nominee Comparison
Nominee Comparison 17 Public Company Board Experience CEO/CFO/ COO Finance and M&A Operations Transformation / Strategy Paper Industry Independent Diverse Twin Rivers / Atlas Group Conflict Repeat Lapetus Nominee Dr. Robert K. Beckler ✓ ✓ ✓ ✓ ✓ ✓ Paula Cholmondeley ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Randy Nebel ✓ ✓ ✓
Slide 19: Corporate Governance Improvements — Compensation
Corporate Governance Improvements — Compensation 18 41 board meetings were held in 2019; Messrs. Carr, Davis, Scheiwe and Nebel and Ms. Taylor attended 100% of the board meetings during their tenure ; Mr. Shuster attended 40 out of 41 Eliminated Strategic Alternatives Committee compensation in Septe
Slide 20: Atlas/Blue Wolf's Intentions and Claims
Atlas/Blue Wolf’s Intentions and Claims
Slide 21: Timeline of Engagement with Atlas/Blue Wolf
Timeline of Engagement with Atlas/Blue Wolf 20 For the past two years, members of the Board and management team have held numerous discussions with representatives of Atlas/Blue Wolf These discussions began with an unsolicited, conditional and opportunistic all - cash proposal by Atlas/Blue Wolf to
Slide 22: Atlas/Blue Wolf's Self-Serving Agenda
Atlas/Blue Wolf’s Self - Serving Agenda 21 Consistent with best practice corporate governance principles, the Board conducted an extensive and rigorous interview proces s with the Atlas/Blue Wolf nominees, just as it does with any other Board nominees. The Board determined the Atlas/Blue Wolf nomine
Slide 23: Atlas/Blue Wolf's Nominees Are Highly Conflicted and Not Additive
Atlas/Blue Wolf’s Nominees Are Highly Conflicted and Not Additive 22 Why else would Atlas/Blue Wolf be running a proxy contest against a newly refreshed, diverse and experienced Board of Directors when their investment has increased nearly 18% over the past two years to the record date, if not becau
Slide 24: Atlas/Blue Wolf's False Claim: Value Creation Strategy
23 Atlas alleges that: It lacks confidence in the Board’s ability to establish and execute a value creation strategy for the Company and manage capital investments wisely Verso sets the record straight: x Company delivered record stock performance and strong financial performance in 2018 x As macro
Slide 25: Atlas/Blue Wolf's False Claim: Board Experience
24 Atlas/Blue Wolf’s False Claim Atlas alleges that: Current lacks experience in specialty, graphic paper and bleached market pulp and their nominees offer operational and turnaround experience Verso sets the record straight: x With the current slate of nominees, the Board believes that it has direc
Slide 26: Atlas/Blue Wolf's False Claim: Board Compensation
25 Atlas/Blue Wolf’s False Claim Atlas alleges that: • Board compensation is excessive compared to public companies of much larger size • Directors only receive ~25% of their total compensation in stock • The Board’s Co - Chairmen each received the Board Chair fee • Executives and directors collecti
Slide 27: Atlas/Blue Wolf's False Claim: Stevens Point and Androscoggin Sale
26 Atlas/Blue Wolf’s False Claim Atlas alleges that: Stevens Point mill is the “crown jewel” of Verso and that stockholders should expect full value, and also that Verso is losing significant value through the sale of the Androscoggin mill Verso sets the record straight: x Conducted thorough and com
Slide 28: Conclusion
Verso Board and Management: Track Record of Strong Performance Verso’s Stock Has Outperformed Its Peers and Russell 2000 Verso will have a Highly Qualified, Diverse & Newly Refreshed Board: Paper Industry, Transformational, M&A & Public Co. Experience Verso is expected to return Significant Capital
Slide 29: Appendix A
VERSO. Appendix A
Slide 30: Verso Nominee: Dr. Robert K. Beckler
Verso Nominee: Dr. Robert K. Beckler 29 Dr. Robert K. Beckler Dr. Beckler is the owner of RKB Consulting, LLC, which he founded in September 2016. He served as President, Packaging Solutions, of WestRock Company (“WestRock”), a provider of packaging solutions and manufacturer of containerboard and p
Slide 31: Verso Nominee: Paula H.J. Cholmondeley
Verso Nominee: Paula H.J. Cholmondeley 30 Paula H.J. Cholmondeley Ms. Cholmondeley is the principal for The Sorrel Group, a corporate governance consulting firm she founded in 2004. She has served as a director for Terex Corporation, an international industrial products company, since 2004, as well
Slide 32: Verso Nominee: Randy J. Nebel
Verso Nominee: Randy J. Nebel 31 Randy J. Nebel Mr. Nebel has been a director of Verso since November 14, 2019. Mr. Nebel is the sole owner of RJNebel Consulting, which he founded in February 2019. From January 2017 to November 2018, he was the Executive Vice President of Integrated Packaging of Kap
Slide 33: Verso Nominee: Steven D. Scheiwe
Verso Nominee: Steven D. Scheiwe 32 Steven D. Scheiwe Mr. Scheiwe has been a director of Verso since October 2016. He has been the President of Ontrac Advisors, Inc., a consultancy providing business analysis and management services to private equity firms, companies and funds managing distressed de
Slide 34: Verso Nominee: Jay Shuster
Verso Nominee: Jay Shuster 33 Jay Shuster Mr. Shuster has been a director of Verso since July 2016. He has been the Managing Member of Shuster Group, LLC, a privately held business consulting firm begun in 2000, through which he has advised industrial and consumer products companies on strategic and
Slide 35: Verso Nominee: Adam St. John
Verso Nominee: Adam St. John 34 Adam St. John Mr. St. John has been our Chief Executive Officer and a director since his appointment by the board of directors on November 11, 2019. Prior to that, Mr. St. John served as our Senior Vice President of Manufacturing since August 2016. He previously serve
Slide 36: Verso Nominee: Nancy M. Taylor
Verso Nominee: Nancy M. Taylor 35 Nancy M. Taylor Ms. Taylor has been a director of Verso since November 14, 2019. Ms. Taylor was President and Chief Executive Officer of Tredegar Corporation, a global manufacturing company, from February 2010 to June 2015. Prior to serving as President and Chief Ex
Slide 37: Appendix B
VERSO. Appendix B
Slide 38: Non-GAAP Financial Measures
Non - GAAP Financial Measures 37 This presentation contains certain non - GAAP measurements, including EBITDA and Adjusted EBITDA, that management believes are meaningful to investors because they provide useful perspective on underlying business trends (i.e., trends excluding non - recurring or unu
Slide 39: Q4 2017 and FY 2017 P&L Adjusted EBITDA add back items
Q4 2017 and FY 2017 P&L Adjusted EBITDA add back items 38 The table below shows the Company’s consolidated income statement as presented under U.S. GAAP in the first column, then adjusted to reflect the adjustments the Company uses to get from EBITDA to Adjusted EBITDA. (1) (2) (3) (4) (5) Costs ass
Slide 40: 2017 to 2018 Adjusted EBITDA
2017 to 2018 Adjusted EBITDA 39 (Dollars in millions) 2017 2018 YoY Δ Net income (loss) (30)$ 171$ 201$ Income tax expense (benefit) (8) - 8 Interest expense 38 33 (5) Depreciation and amortization 115 111 (4) EBITDA 115$ 315$ 200$ Restructuring charges 9 1 (8) Non-cash equity award compensation 1 8
Slide 41: Verso Post Transaction LTM Adjusted EBITDA Reconciliation
Verso Post Transaction LTM1 Adjusted EBITDA Reconciliation 40 Verso Androscoggin & Stevens Point Verso Post Transaction (Dollars in millions, except per share amounts) 12 Months Ended September 30, 2019 12 Months Ended September 30, 2019 12 Months Ended September 30, 2019 Net sales $ 2,552 $ 546 $ 2